Intercept Pharmaceuticals, Inc.
ICPT · NASDAQ
9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Market Cap | $774,824 | $461,545 | $559,628 | $511,166 |
| - Cash | $102,736 | $136,229 | $61,404 | $50,517 |
| + Debt | $223,856 | $333,411 | $333,040 | $332,673 |
| Enterprise Value | $895,944 | $658,727 | $831,264 | $793,322 |
| Revenue | $88,789 | $83,718 | $67,958 | $77,219 |
| % Growth | 6.1% | 23.2% | -12% | – |
| Gross Profit | $88,592 | $83,533 | $67,736 | $77,190 |
| % Margin | 99.8% | 99.8% | 99.7% | 100% |
| EBITDA | $5,146 | $1,091 | -$26,512 | -$14,737 |
| % Margin | 5.8% | 1.3% | -39% | -19.1% |
| Net Income | -$2,790 | -$5,862 | -$29,575 | -$20,383 |
| % Margin | -3.1% | -7% | -43.5% | -26.4% |
| EPS Diluted | -0.067 | -0.14 | -0.71 | -0.49 |
| % Growth | 52.3% | 80.3% | -44.9% | – |
| Operating Cash Flow | $16,686 | -$23,302 | -$51,597 | -$4,806 |
| Capital Expenditures | -$13 | -$98 | $0 | $297 |
| Free Cash Flow | $16,673 | -$23,400 | -$51,597 | -$4,509 |